Takeda Focuses on Reducing Debt as Vyvanse Patent Loss Looms

The drugmaker Takeda has ramped up its efforts in reducing its debt burder, with plans to pay off another 500 billion yen of debt by the end of the year. While the company had pivoted its efforts towards cutting its debt since its acquisition of Shire, the new focus comes as its ADHD drug Vyvanse is set to lose market exclusivity in August of next year.

According to Angus Liu of Fierce Pharma, “Takeda has paid off much of its debt by jettisoning “non-core” assets beyond the areas of gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology and neuroscience. Now, as the series of divestments are “essentially complete,” Takeda is shifting its focus toward driving revenue growth.”

To read more, click here,

(Source: Fierce Pharma, May 11^th, 2022)